Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
The purpose of this study is to determine whether the study drug is effective and safe in the first line treatment of patients with small cell lung cancer
Small Cell Lung Carcinoma
DRUG: Sagopilone (BAY86-5302, ZK 219477)
Response to treatment according to the modRECIST (complete response or partial response), Every 2 cycles until tumor progression i.e. approximately every 6 weeks
Duration of complete or partial tumor response, Every 2 cycles until tumor progression i.e. approximately every 6 weeks|Time to tumor progression, Every 2 cycles until tumor progression i.e. approximately every 6 weeks|Number of participants with adverse events, Approximately 30 weeks
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.